Shares of Shire PLC (LON:SHP) have been given a consensus recommendation of “Buy” by the nineteen brokerages that are covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is GBX 4,937.50 ($68.22).
A number of research firms have weighed in on SHP. Liberum Capital reissued a “hold” rating and issued a GBX 4,000 ($55.26) price objective on shares of Shire in a research report on Wednesday. Societe Generale cut their target price on shares of Shire from GBX 8,000 ($110.53) to GBX 7,500 ($103.62) and set a “buy” rating on the stock in a research note on Wednesday, February 28th. Credit Suisse Group restated an “outperform” rating and issued a GBX 4,000 ($55.26) target price on shares of Shire in a research note on Monday. Shore Capital restated a “buy” rating on shares of Shire in a research note on Friday, February 23rd. Finally, Barclays restated an “equal weight” rating and issued a GBX 3,650 ($50.43) target price on shares of Shire in a research note on Thursday, February 15th.
In other Shire news, insider Dominic Blakemore acquired 165 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The shares were purchased at an average price of GBX 3,790 ($52.36) per share, for a total transaction of £6,253.50 ($8,639.82).
Shire (LON SHP) opened at GBX 3,229.50 ($44.62) on Wednesday. The firm has a market cap of $29,380.00 and a PE ratio of 2,211.99. Shire has a 12-month low of GBX 2,940.50 ($40.63) and a 12-month high of GBX 5,038 ($69.60).
The firm also recently disclosed a dividend, which will be paid on Tuesday, April 24th. Investors of record on Thursday, March 8th will be paid a dividend of GBX 21.46 ($0.30) per share. This is a positive change from Shire’s previous dividend of $3.85. The ex-dividend date is Thursday, March 8th. This represents a yield of 0.67%.
COPYRIGHT VIOLATION WARNING: This article was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/14/shire-plc-shp-receives-average-rating-of-buy-from-analysts.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.